Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Huilai Zhang"'
Autor:
Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai
Publikováno v:
Cancer Medicine. 11:4134-4145
Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib-based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real-world efficacy and sa
Autor:
Huijuan Lv, Yue Fei, Wei Li, Yi Wang, Jinni Wang, Jin He, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Dehui Zou, Qingqing Cai, Xianhuo Wang, Huilai Zhang
Publikováno v:
Hematological Oncology. 40:343-355
The mantle cell lymphoma (MCL) International Prognostic Index (MIPI) and combined MIPI (MIPI-c) are commonly used for risk classification of MCL patients. However, these indexes lack immune-related parameters. The purpose of this study was to develop
Autor:
Lanfang Li, Xianhuo Wang, Jin He, Sicong Zhang, Bin Meng, Jing Zhao, Xiaoxing Su, Shiyong Zhou, Lihua Qiu, Hengqi Liu, Tingting Zhang, Huilai Zhang, Xiubao Ren, Zhengzi Qian, Haifei Zhou, Xianming Liu, Wenchen Gong
Publikováno v:
British Journal of Haematology. 196:617-628
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established
Autor:
Xiubao Ren, Lanfang Li, Tianyuan Ren, Zheng Song, Zhengzi Qian, Huilai Zhang, Xianhuo Wang, Jin He, Lihua Qiu, Tingting Zhang, Qiongli Zhai, Shiyong Zhou, Xianming Liu, Jing Zhao, Bin Meng, Lei Jiao, Zhenzhen Zhang
Publikováno v:
Journal of Immunology Research, Vol 2020 (2020)
Journal of Immunology Research
Journal of Immunology Research
Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies. However, there remains a conside
Autor:
Lanfang Li, Wengui Xu, Xianhuo Wang, Huilai Zhang, Wenchao Ma, Zheng Song, Lihua Qiu, Shiyong Zhou, Peiqi Zhao, Lei Zhu, Zhengzi Qian, Xiang Zhu
Publikováno v:
Hematological Oncology. 38:493-500
The aim was to build a prognostic model to stratify patients at diagnosis into different risk categories. We investigated the prognostic value of functional PET parameters and clinical features in 64 primary breast lymphoma (PBL) patients. With a med
Autor:
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu
Publikováno v:
Blood. 139(21)
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received ≥1 prior therapy. We re
Autor:
Hua-wei Weng, Tongyu Lin, Tao Pan, Hong-wei Xue, Zegeng Chen, Li-qun Zou, Ya-wen Wang, Wei Zhang, Huangming Hong, Xiaojie Fang, He Huang, Hongqiang Guo, Yong-chang Chen, Fei Pan, Li-min Chen, Ke Xie, Zhao Wang, Huilai Zhang, Yuan-yuan Shen, Meiting Chen, Xu-dong Li, Xiaoqian Li, Hui-juan Lv, Yuyi Yao, Hui Zhou
Publikováno v:
BMC Cancer
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Background Adult sporadic Burkitt lymphoma (BL) is a rare but highly aggressive subtype of lymphoma which lacks its own unique prognostic model. Systemic inflammatory biomarkers have been confirmed as prognostic markers in several types of malignancy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e504e66f592b81ff9139b53f8856c85f
https://doi.org/10.21203/rs.3.rs-522334/v1
https://doi.org/10.21203/rs.3.rs-522334/v1
Autor:
Zhengzi Qian, Xiubao Ren, Lanfang Li, Yuheng Hong, Lihua Qiu, Huilai Zhang, Shiyong Zhou, Xianhuo Wang, Qiqi Zhou, Ge Hu, Qingpei Guan
Publikováno v:
Hematological oncologyREFERENCES. 39(4)
This study aimed to identify the prognostic factors in patients with Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL), comparing the efficacy of radiotherapy (RT) for the WR-DLBCL patients in the pre-rituximab and rituximab eras. We conducted
Autor:
Young Rok Do, Zhu Jun, Weili Zhao, Hyeok Shim, Jung Hye Kwon, Yeung-Chul Mun, Young Il Koh, Ka Won Kang, Jae Yong Kwak, Ye Guo, Seong Kyu Park, Ho Sup Lee, Cosphiadi Irawan, Young Hyeh Ko, Kevin Tay Kuang Wei, Hyo Jung Kim, Yong Pyo Lee, Won Seog Kim, Won Sik Lee, Huilai Zhang, Hwan Jung Yun, Seok Jin Kim, Sung Yong Oh, Mark Hong Lee, Tsai Yun Chen, Hye Jin Kang, Dok Hyun Yoon, Byeong Seok Sohn, Jae Cheol Jo, Jae Joon Han, Sang Eun Yoon, Yuqin Song, Soo Chin Ng, Daryl Tan Chen Lung, Michelle Poon, Soon Thye Lim
Publikováno v:
International journal of hematology. 114(3)
Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet been established for advanced CTCLs. In this study, relative incidence of CTCLs in Asia wa
Publikováno v:
Hematological Oncology. 36:779-785
Interstitial pneumonia (IP) is one of the potentially fatal adverse events for lymphoma patients undergoing immunochemotherapy. However, the risk factors and predictive markers remain unclear for this complication. This retrospective study aims to ex